Prognostic factors of oncologic outcomes in metastatic chemotherapy naive castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Se Young | - |
dc.contributor.author | Ryu, Jeman | - |
dc.contributor.author | You, Dalsan | - |
dc.contributor.author | Jeong, In Gab | - |
dc.contributor.author | Hong, Jun Hyuk | - |
dc.contributor.author | Ahn, Hanjong | - |
dc.contributor.author | Kim, Choung-Soo | - |
dc.date.accessioned | 2024-01-18T07:00:32Z | - |
dc.date.available | 2024-01-18T07:00:32Z | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 1078-1439 | - |
dc.identifier.issn | 1873-2496 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/71080 | - |
dc.description.abstract | Objectives: We aimed to evaluate the prognostic factors for chemotherapy-naive castration-resistant prostate cancer (CRPC) treated with enzalutamide in actual clinical practice using easily accessible clinical variables. Methods and materials: We retrospectively reviewed the following data from 113 patients with chemotherapy-naive CRPC treated with enzalutamide: serum levels of prostate-specific antigen (PSA), testosterone, hemoglobin, total protein, albumin, and alkaline phosphatase (ALP); platelet, neutrophil, and lymphocyte counts; neutrophil-to-lymphocyte ratios (NLRB); and liver profiles. PSA progression-free survival (PFS), radiological PFS, and overall survival were estimated by Cox regression analysis. Results: Compared with baseline levels, laboratory values at 2 months showed significantly lower PSA (160.2 351.5 ng/ml vs. 47.4 117.1 ng/ml) and ALP levels (201.86 223.77 IU/1 vs. 148.25 146.81 IU/1) and a significantly higher percentage of lymphocytes (28.1% 10.6% vs. 31.2% 9.7%); those at 1 month showed a significantly lower percentage of neutrophils (61.0% 11.0% vs. 57.1% 12.5%). In the multivariate analysis, poor prognostic factors for PSA PFS were Gleason score > 9 (hazard ratio [HR] 2.022; P = 0.0250); visceral metastasis (HR 3.143; P = 0.0002); high NLR (HR 1.205; P = 0.0126); and high ALP (HR 1.002; P = 0.0015). For radiological PFS, high NLR (HR 1.249; P = 0.0002) and high ALP (HR 1.002; P = 0.0001) were associated with poor outcomes. The predictors of poor overall survival were visceral metastasis (HR 3.155; P < 0.0001); high NLR (HR 1.341; P < 0.0001); and high ALP (HR 1.001; P = 0.0017). Conclusion: Enzalutamide is less effective in patients with metastatic chemotherapy-na ve CRPC with Gleason scores > 9, visceral metastasis, high NLR, and high ALP. (C) 2018 Elsevier Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Prognostic factors of oncologic outcomes in metastatic chemotherapy naive castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.urolonc.2018.06.004 | - |
dc.identifier.bibliographicCitation | UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, v.36, no.9 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000445905300006 | - |
dc.identifier.scopusid | 2-s2.0-85054095417 | - |
dc.citation.number | 9 | - |
dc.citation.title | UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | - |
dc.citation.volume | 36 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Castration-resistant prostate cancer | - |
dc.subject.keywordAuthor | Enzalutamide | - |
dc.subject.keywordAuthor | Neutrophil-to-lymphocyte ratio | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Biomarker | - |
dc.subject.keywordPlus | LYMPHOCYTE RATIO | - |
dc.subject.keywordPlus | END-POINTS | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MITOXANTRONE | - |
dc.subject.keywordPlus | PREDNISONE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | TRIALS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.